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ﬁbrillation (AF) recurrence in patients with obstructive sleep apnea (OSA) undergoing pulmonary vein isolation (PVI).Background OSA is a predictor of AF recurrence following PVI. However, the impact of CPAP therapy on PVI outcome in patients
with OSA is poorly known.Methods Among 426 patients who underwent PVI between 2007 and 2010, 62 patients had a polysomnography-conﬁrmed
diagnosis of OSA. While 32 patients were “CPAP users” the remaining 30 patients were “CPAP nonusers.” The
recurrence of any atrial tachyarrhythmia, use of antiarrhythmic drugs, and need for repeat ablations were compared
between the groups during a follow-up period of 12 months. Additionally, the outcome of patients with OSA was
compared to a group of patients from the same PVI cohort without OSA.Results CPAP therapy resulted in higher AF-free survival rate (71.9% vs. 36.7%; p ¼ 0.01) and AF-free survival off
antiarrhythmic drugs or repeat ablation following PVI (65.6% vs. 33.3%; p ¼ 0.02). AF recurrence rate of
CPAP-treated patients was similar to a group of patients without OSA (HR: 0.7, p ¼ 0.46). AF recurrence following
PVI in CPAP nonuser patients was signiﬁcantly higher (HR: 2.4, p < 0.02) and similar to that of OSA patients
managed medically without ablation (HR: 2.1, p ¼ 0.68).Conclusions CPAP is an important therapy in OSA patients undergoing PVI that improves arrhythmia free survival. PVI offers
limited value to OSA patients not treated with CPAP. (J Am Coll Cardiol 2013;62:300–5) ª 2013 by the American
College of Cardiology FoundationSee page 306Atrial ﬁbrillation (AF) is the most commonly encountered
arrhythmia in clinical practice and a major cause of
morbidity and mortality (1). Its rising prevalence and asso-
ciated economic cost underscore the importance of effective
therapies (2,3). Pulmonary vein isolation (PVI) is an effec-
tive treatment in selected patients with AF; however, the
relatively high recurrence rate remains an important limita-
tion (4–7). It is well established that the success rate of PVI
is highly dependent of patient characteristics, including age,
obesity, atrial size, the presence of hypertension, mitral valve
disease, and arrhythmia type and duration (8).ophysiology Institute, Cardiovascular Division,
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2012; revised manuscript received February 11,AF is exceedingly prevalent in patients with obstructive
sleep apnea (OSA) (9,10). Mechanisms by which OSA
increases the risk of AF include: 1) intermittent nocturnal
hypoxemia and hypercapnia; 2) enhanced sympathetic tone
with surges in blood pressure during apneic episodes leading
to left atrial stretch through pressure and volume overload;
3) increased oxidative stress and inﬂammatory processescontributing to left atrial remodeling and ﬁbrosis (11–13).
These mechanisms may act as both triggers and perpetua-
tors of AF, potentially explaining the limited efﬁcacy of
arrhythmia-controlling interventions, including pulmonary
vein isolation (14–18). Continuous positive airway pressure
(CPAP) ventilation prevents episodes of hypoxia and
hypercapnia and attenuates the sympathetic tone in patients
with OSA (19,20). While CPAP has been shown to
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301decrease AF recurrence following cardioversion, its effect on
arrhythmia control in patients undergoing AF ablation
procedures is limited (18,21). The purpose of this study was to
examine the effect of CPAP therapy on AF recurrence in
patients with OSA undergoing PVI.BMI = body mass index
CPAP = continuous positive
airway pressure
LAD = left atrial dimension
OSA = obstructive sleep
apnea
PVI = pulmonary vein
isolationMethods
Study population. The study group consisted of consecu-
tive patients with OSA and symptomatic AF identiﬁed from
the prospectively collected database of patients referred for
an index AF ablation procedure at Beth Israel Deaconess
Medical Center (Boston, Massachusetts) from July 2007
to January 2010. The diagnosis of OSA was established by
a single polysomnography study and conﬁrmed by previously
described criteria (22). In brief, OSA was deﬁned as cessa-
tion of airﬂow for >10 s with persistent respiratory effort as
seen in the ribcage or abdominal motion and complemented
by at least 4% fall in O2 saturation. In addition, an apnea
hypopnea index of greater than 15/h with at least 80% of
all events obstructive was required for the deﬁnition of OSA.
To examine the effect of CPAP on arrhythmia recurrence,
the group of patients with OSA was divided into “CPAP
users” [PVI (þ) OSA (þ) CPAP (þ)] and “CPAP non-
users” [PVI (þ) OSA (þ) CPAP (-)]. The diagnosis of
OSA and assignment to therapy groups [CPAP (þ) and
CPAP (-)] was established at least 3 months before the
planned PVI. As such, “CPAP users” had used CPAP daily
for a minimum of 3 months prior to the index PVI and
continued to use CPAP throughout the follow-up duration.
There were no crossovers between the groups.
Study endpoints. The primary study endpoint was freedom
from AF and/or organized atrial tachyarrhythmias at 1 year
after the ﬁrst ablation procedure. The secondary study
endpoint was freedom from AF and/or organized atrial
tachyarrhythmias at 1 year off antiarrhythmic drugs (AADs)
or redo ablation procedures. Arrhythmia recurrence was
deﬁned as any documented atrial tachyarrhythmia episode
lasting for >30 s that occurs after a 2-week blanking period
following the ablation procedure.
In order to assess the effect of OSA itself on arrhythmia
recurrence following PVI, the primary endpoint of
arrhythmia-free survival in patients with OSA (both CPAP
users and CPAP nonusers) was compared to the control
group of 30 patients without the diagnosis of OSA who
underwent a PVI. This group of patient was randomly
selected from the same database [PVI (þ) OSA (-)]. In
addition, we examined the effect of PVI on arrhythmia-free
survival in a cohort of 22 OSA patients using CPAP whose
AF was treated medically [PVI (-) OSA (þ) CPAP (þ)]
with a rhythm control strategy. This cohort of patients was
identiﬁed through International Classiﬁcation of Diseases 9
coding of the institutional billing records for the same period
of time (July 2007 to January 2010) and was not part of the
AF ablation database. Similar to the ablation groups, this
group of patients was followed by a cardiologist anda rhythm control strategy was
attempted by either electrical car-
dioversion and/or antiarrhythmic
drug therapy. The study protocol
and consent forms were approved
by the Institutional Review Board.
Ablation protocol. All AADs,
except amiodarone, were discon-
tinued 5 half-lives before the
procedure (amiodarone was dis-
continued 2 weeks before the
procedure).Our standard approach
to AF ablation has been previ-
ously described (23). Brieﬂy, diagnostic decapolar catheters
were placed in the coronary sinus and the anterolateral right
atrium. An intracardiac ultrasound catheter (AcuNav, Bio-
sense Webster, Inc, Diamond Bar, California) was placed in
the right atrium. Two transseptal punctures were made,
through which the mapping/ablation catheter and the
multielectrode circular mapping catheters (Lasso, Biosense
Webster) were advanced into the left atrium. Unfractionated
heparin was administered to maintain an activated clotting
time of 250 to 350 s for the duration of the procedure.
PVI was performed by isolating all pulmonary veins with
demonstration of entrance and exit block from each vein.
After PVI, isoproterenol infusion to effect was administrated
to examine acute reconnection and to identify nonpulmonary
vein triggers. Left atrial ablation lines (roof line, mitral
isthmus line, and/or posterior left atrial line) or ablation of
extra-PV atrial triggers were performed in patients with
inducible sustained AF or atrial tachyarrhythmia at the
operator’s discretion on the basis of electroanatomic mapping
information obtained during the arrhythmia. At the initiation
of the study, our center was performing AF ablation using the
8-mm-tip catheter (NaviStar, Biosense Webster); however,
during the study, we switched to a 3.5-mm open irrigation tip
catheter (Navistar Thermocool, Biosense Webster).
Follow-up. After the procedure, patients were adminis-
tered AADs (usually class IC agents or sotalol) and warfarin.
Long-term follow-up consisted of both clinic visits (1, 3, 6,
and 12 months) and 2-week transtelephonic monitoring
(with auto- and patient-trigger capabilities) at 3, 6, and
12 months. Additional transtelephonic monitoring was
performed based on symptoms between visits. At each
outpatient visit, patients were queried for symptoms and a
12-lead electrocardiogram was obtained. In the absence
of any documented arrhythmia recurrence, AADs were
discontinued between 3 and 6 months after the initial
procedure. Patients with documented recurrence of atrial
tachyarrhythmias were treated with AADs or offered repeat
ablation procedures at their provider’s discretion. In patients
undergoing a repeat ablation, the same follow-up approach
was used. The follow-up duration of the study was 1 year.
Data collection. All data including clinical patient char-
acteristics, comorbidities, medication history, and follow up
was retrospectively collected from the review of the
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302electronic medical records. Compliance with CPAP therapy
was part of standard pre-procedural evaluation as well as
follow-up clinic visits. Most patients had a cardiac magnetic
resonance imaging prior to PVI, allowing for determination
of the left ventricular ejection fraction and left atrial size
measurements. For the small number of patients without
a magnetic resonance imaging, anatomic data was recorded
from transthoracic echocardiogram or cardiac computed
tomography. Left atrial diameter was recorded from the
4-chamber view, irrespective of modality. The size of the left
atrium was not assessed in non-PVI control group, as they
did not undergo corresponding pre-procedure imaging.
Statistical analysis. Baseline clinical variables were com-
pared between groups using Kruskal-Wallis (continuous
variables) and chi-square tests (categorical variables). Event-
free survival was estimated by the Kaplan-Meier survival
function. Pairwise comparisons of survival rates were made
using log-rank test. The impact of the following variables on
event-free survival was assessed in a univariate Cox regres-
sion analysis: age, gender, left atrial size, body mass index
(BMI), ejection fraction, the presence of hypertension,
diabetes, coronary artery disease, and AF form (paroxysmal
or persistent). Variables demonstrating signiﬁcant impact on
survival were evaluated in a multivariate model. Conﬁdence
intervals for parameter estimates were calculated using
bootstrapping technique. A p value <0.05 was considered
statistically signiﬁcant. Analyses were conducted using IBM
SPSS Statistics 20.0 (Chicago, Illinois).Results
Baseline patient characteristics. From July 2007 to
January 2010, 426 patients with symptomatic AF wereFigure 1 Study Cohort: Flowchart
Flow diagram showing the establishment of the study cohort and division into treatment gro
airway pressure; OSA ¼ obstructive sleep apnea; pts ¼ patients; PVI ¼ pulmonary vein ireferred to our institution for an index PVI. Forty patients
with insufﬁcient data (most lived at a distance and lost to
follow-up) were excluded. From the remainder, 62 patients
(16%) had a polysomnography-conﬁrmed diagnosis of
OSA. Thirty-two patients with OSA (51.6%) were CPAP-
users while 30 patients (48.4%) were CPAP nonusers
(Fig. 1). There were no signiﬁcant clinical differences
between the 2 OSA groups and between the OSA groups
and the 2 control groups (Table 1). Importantly, all 4 groups
were balanced in regard to BMI, left atrial size, percentage of
persistent AF, and number of failed AADs. The majority of
patients were hypertensive and male, had a BMI that was
near obese, equally split between persistent and paroxysmal
AF, and were treated with an average of 1.4 antiarrhythmic
medications.
CPAP therapy and arrhythmia recurrence following
ablation. During a follow-up period of 1 year, 23 of the
32 “CPAP-users” [PVI (þ) OSA (þ) CPAP (þ)], 11 of the
30 “CPAP nonusers” [PVI (þ) OSA (þ) CPAP (-)], and 20
of the 30 non-OSA patients [PVI (þ) OSA (-)] remained in
SR following the ﬁrst PVI. The atrial tachyarrhythmia–free
survival rate was signiﬁcantly higher in the “CPAP users”
compared with the “CPAP nonusers” (71.9% vs. 36.7%;
p ¼ 0.01); and similar to that of patients without OSA
(66.7%; p ¼ 0.94) (Fig. 2).
Arrhythmia-free survival off AADs/repeat ablation
was signiﬁcantly higher in the “CPAP users” group com-
pared with the “CPAP nonuser” group (65.6% vs. 33.3%;
p ¼ 0.02).
There was no signiﬁcant difference in the frequency of
repeat ablation procedures between the CPAP-users, CPAP
nonusers, and non-OSA control group (15.6%, 26.7%, and
20%, respectively; p ¼ 0.56).ups (shown in dark gray and control groups in light gray). CPAP¼ continuous positive
solation.
Table 1 Baseline Characteristics of Study Groups
Variable
PVI (þ) / OSA (þ) /
CPAP (þ) (n ¼ 32)
PVI (þ) / OSA (-) /
CPAP (-) (n ¼ 30)
PVI (þ) / OSA (-) /
CPAP (-) (n ¼ 30)
PVI (-) / OSA (þ) /
CPAP (þ) (n ¼ 22) p Value
Age, yrs 56.8  1.2 58.5  1.4 58.5  1.4 55.0  1.6 0.27
Male 23 (76.7) 23 (71.9) 23 (71.9) 16 (72.7) 0.96
BMI, kg/m2 28.77  0.45 29.58  0.40 29.58  0.40 30.69  0.99 0.11
Persistent AF 17 (56.7) 16 (50.0) 16 (50.0) 12 (54.5) 0.95
Hypertension 21 (70.0) 21 (65.6) 21 (65.6) 15 (68.2) 0.81
Diabetes 6 (20.0) 6 (18.6) 6 (18.6) 4 (18.2) 1.00
CAD 8 (26.7) 6 (18.6) 6 (18.6) 5 (22.7) 0.88
LVEF, % 60.2  1.5 59.5  0.94 59.5  0.94 59.3  2.0 0.96
LAD, mm 54.5  0.91 55.9  1.1 55.9  1.1 d 0.51*
No. AAD 1.47  0.12 1.34  0.10 1.34  0.10 1.00  0.15 0.07
Values are mean  SE or n (%). * ¼ LAD was not available in PVI (-) group.
AAD ¼ antiarrhythmic drugs; AF¼ atrial ﬁbrillation; BMI ¼ body mass index; CAD ¼ coronary artery disease; CPAP ¼ continuous positive airway pressure; LAD ¼ left atrial dimension; LVEF ¼ left ventricular
ejection fraction; OSA ¼ obstructive sleep apnea; PVI ¼ pulmonary vein isolation.
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303The effect of PVI on arrhythmia recurrence in patients
with OSA. The effect of PVI on arrhythmia-free survival
in patients with OSA was examined by comparing the group
of CPAP-users patients who underwent PVI with a group of
CPAP-treated OSA patients [PVI (-) OSA (þ) CPAP (þ)]
with AF who were treated medically (Fig. 2). Arrhythmia-
free survival was signiﬁcantly higher in the group of
patients who underwent PVI (71.9% vs. 45.5%; p ¼ 0.02).
Clinical variables associated with AF recurrence. Because
left atrial dimension (LAD) data were not available for the
PVI (-) group, 2 separate sets of analyses were performed,
1 for the 3 PVI (þ) groups, and 1 for all 4 groups. In
univariate analysis in PVI (þ) groups only LAD was
negatively associated with AF-free survival (p < 0.01). LAD
then was entered into a multivariate model that includedFigure 2
Kaplan-Meier Survival Curves According to
Treatment Group
Log-rank p ¼ 0.02. AF ¼ atrial ﬁbrillation; other abbreviations as in Figure 1.group designation as the second variable. The PVI (þ)
OSA (-) group served as control for pairwise comparisons.
The PVI (þ) OSA (þ) CPAP (-) patients had more than
2-fold increased risk of AF recurrence (hazard ratio [HR]:
2.15; 95% conﬁdence interval: 1.10 to 5.44; p ¼ 0.02)
following PVI (Table 2). In contrast, CPAP-treated patients
had event-free survival similar to that of patients without
OSA (HR: 0.7; 95% conﬁdence interval: 0.3 to 1.59;
p ¼ 0.39). LAD was associated with the risk of AF recur-
rence (HR per mm increase: 1.1; p < 0.01).
In a 4-group univariate analysis the presence of hyper-
tension (p ¼ 0.04) and persistent AF (p < 0.01) were
negatively associated with AF-free survival.
These variables were included in the second multivariate
model. The PVI (-) group was used as the control for
pairwise comparisons. Both PVI (þ) OSA (-) and PVI (þ)
OSA (þ) CPAP (þ) groups demonstrated approximately
2-fold AF risk reduction (HR: 0.48 to 0.52; p < 0.05). In
contrary, the PVI (þ) OSA (þ) CPAP (-) group showed an
AF recurrence rate similar to the PVI (-) group (HR: 1.12;
p ¼ 0.65). The presence of HTN and persistent AF were
associated with approximately 2-fold increase in AF recur-
rence risk (Table 3).
Discussion
Major ﬁndings. The main ﬁndings of the study are:
1) OSA patients treated with CPAP had signiﬁcantlyTable 2
Multivariate Predictors of AF Recurrence in PVI (þ)
Patients (Comparison to PVI (þ) OSA (-) Group)
Multivariate
Hazard Ratio 95% Conﬁdence Interval p Value
LAD 1.1 per mm
increase
1.04–1.18 0.003
PVI (D) OSA (D)
CPAP (D)
0.7 0.3–1.59 0.39
PVI (D) OSA (D)
CPAP (-)
2.15 1.10–5.44 0.02
Abbreviations as in Table 1.
Table 3
Multivariate Predictors of AF Recurrence
(Comparison to PVI (-) Group)
Hazard Ratio 95% Conﬁdence Interval p Value
Persistent AF 1.91 1.27–3.22 0.007
HTN 2.16 1.15–5.23 0.015
PVI (D) OSA (-) 0.53 0.25–0.96 0.048
PVI (D) OSA (D)
CPAP (D)
0.48 0.22–0.91 0.03
PVI (D) OSA (D)
CPAP (-)
1.12 0.71–1.92 0.65
HTN ¼ hypertension; other abbreviations as in Table 1.
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304improved outcome following PVI with overall lower
arrhythmia recurrence rate; and 2) Arrhythmia-free survival
off AADs was signiﬁcantly higher in patients treated with
CPAP. In fact, CPAP therapy resulted in improved
arrhythmia-free survival that was not different than those of
patients without OSA. Conversely, we found that untreated
OSA patients had increased risk of arrhythmia recurrence
that was similar to OSA patients treated medically without
PVI. We found no difference in the rates of repeat PVI
procedures performed between the groups.
Relationship between OSA and AF. OSA is increasingly
recognized as a potential risk factor for the development of
AF. While the mechanisms by which OSA predisposes to
the development and recurrence of AF is uncertain, recent
work by Dimitri et al. demonstrated OSA patients to have
both structural and electrical atrial changes (24). They found
that OSA resulted in pronounced atrial ﬁbrosis as man-
ifested by intra-atrial conduction delay, reduced atrial
voltage, presence of complex atrial electrograms, and elec-
trical silence. These substrate changes may potentially
contribute to the development and maintenance of AF (24).
The interdependence of AF duration, increased atrial pres-
sure, and left atrial structural changes were reﬂected in our
multivariate modeling. Additionally, various hemodynamic
changes, autonomic dysregulation, and increased oxidative
stress during apneic episodes may contribute to AF initia-
tion. The effects of CPAP therapy on reversing these
changes have not been yet determined.
Effects of CPAP therapy. Prior research has shown the use
of CPAP therapy in the treatment of OSA to be effective
in mitigating the burden of AF and improving the effec-
tiveness of AF treatments. In a Japanese study, the use of
CPAP reduced the occurrence of paroxysmal AF and
other arrhythmias during polysomnography (25). In a small
prospective observational study, Kanagala et al. showed that
patients with CPAP-treated OSA had almost half the rate
of AF recurrence compared to untreated patients after car-
dioversion (21).
OSA has also been associated with a greater risk of AF
recurrence after catheter-based AF ablation (15,18). We
found that in the non-OSA patient population, arrhythmia-
free survival at 1 year approximated 70% compared with 53%
in an otherwise matched group of OSA patients. This is
consistent with the divergent success rates reported byJongarangsin et al. (63% and 41%) and more dramatic than
described by Patel et al. (78% and 71%) (15,18).
Our analysis shows that CPAP therapy is associated with
better procedural outcome in the OSA patient population
undergoing PVI. We demonstrated CPAP to be so efﬁca-
cious that OSA treated patients had an arrhythmia recur-
rence rate that matched that of patients without the
diagnosis of OSA. In contrast, CPAP nonusers were over
2 times more likely to have arrhythmia recurrence compared
to CPAP users. Importantly, we found that PVI offered
minimal beneﬁt to OSA patients that were not compliant
with CPAP, with rates of AF recurrence no different than
OSA patients managed medically. These ﬁndings suggest
that unless a patient is “optimized” from the standpoint of
OSA, there may be little value in pursuing invasive treat-
ment procedures.
Study limitations. The principle limitation of the present
study was that it is a retrospective evaluation of a prospec-
tively collected database and therefore can be a subject to
selection bias. Importantly, polysomnography was not per-
formed systematically in all patients but per clinical suspi-
cious again subjected to selection bias and underdiagnoses of
OSA. Limited data regarding the severity of a patient’s OSA
and details of its management were available. While we saw
no signiﬁcant differences in clinical demographics between
the study groups, inherent unaccounted confounders in
these nonrandomized groups may be present. Similarly, the
patients not using CPAP might generally be less compliant
with medical regimen, in turn exaggerating the effects of
CPAP. Decisions to use AAD and repeat ablation proce-
dures were left to the discretion of the treating physicians
and were not controlled for.
The medical management control group represents a
different patient population, and the clinical details that
prompted medical management versus those patients
referred for ablation could not be captured. Some caution
should be made in extrapolating too much from its com-
parison to the ablation group. Last, OSA is often under-
diagnosed; therefore, the incidence of OSA in our patient
population may be underrepresented.
Last, the fairly small number of patients and endpoints
may have resulted in overﬁtting of the multivariate model.
In attempt to minimize this possibility, we included only
variables that demonstrated signiﬁcance in univariate testing
and performed bootstrapping to support the validity of
our multivariate model. However, these results have to be
interpreted with caution until conﬁrmed in larger studies.
Conclusions
The presence of OSA with its associated electroanatomical
atrial remodeling not only potentiates the risk to develop
AF, but also limits the success of AF ablation. CPAP
therapy may very well help mitigate these effects, improving
the outcomes of PVI in the OSA patient population. The
higher rates of recurrent AF following PVI seen in CPAP
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305nonusers reinforces the importance of appropriate patient
selection, continuous compliance with CPAP therapy, and
highlights an avenue to further improve long-term success
of ablation. Careful attention should be paid to screening
patients with AF for OSA, especially prior to undergoing
a PVI, and ensuring compliance with CPAP therapy. This
study’s ﬁndings call for a randomized controlled trial eval-
uating the use of CPAP for AF patients with OSA.
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